TLR2 and TLR4 Gene Expression in Peripheral Monocytes in Nondiabetic Hypertensive Patients: The Effect of Intensive Blood Pressure-Lowering

Journal of Clinical Hypertension

Volumn 14, Issue 5, 2012, Pages 330-335

  Marketou, Maria E ^a   Kontaraki, Joanna E ^a   Zacharis, Evangelos A ^a   Kochiadakis, George E ^a   Giaouzaki, Aikaterini ^a   Chlouverakis, Gregory ^b   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATTENUATION; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; ESSENTIAL HYPERTENSION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INTENSIVE CARE; MALE; MONOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FOLDING; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME;

EID: 84860321843     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00620.x     Document Type: Article

References (25)

1. Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician perspective. J Am Soc Hypertens. 2007;1:113-119.
2. Tian N, Penman AD, Mawson AR, et al. Association between circulating specific leukocyte types and blood pressure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Hypertens. 2010;4:272-283.
3. Methe H, Kim JO, Kofler S, et al. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005;111:2654-2661.
4. Foldes G, von Haehling S, Okonko DO, et al. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol. 2008;124:80-85.
5. Wolf G, Bohlender J, Bondeva T, et al. Angiotensin II upregulates Toll-like receptor 4 on mesangial cells. J Am Soc Nephrol. 2006;17:1585-1593.
6. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
7. Turnbull F, Neal B, Algert C, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
8. Verdecchia P, Staessen JA, Angeli F, et al.; On behalf of the Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525-533.
9. Mancia G, de Backer G, Dominiczak A, et al.; Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1751-1762.
10. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
11. Edfeldt K, Swedenborg J, Hansson GK, et al. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158-1161.
12. Björkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol. 2006;17:527-533.
13. Farina C, Theil D, Semlinger B, et al. Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. Int Immunol. 2004;16:799-809.
14. Lemieux I, Poirier P, Bergeron J, et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol. 2007;23:23B-31B.
15. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109:2850-2856.
16. Hollestelle SC, De Vries MR, Van Keulen JK, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation. 2004;109:393-398.
17. Pasterkamp G, Galis ZS, de Kleijn DP. Expansive arterial remodeling: location, location, location. Arterioscler Thromb Vasc Biol. 2004;24:650-657.
18. Eissler R, Schmaderer C, Rusai K, et al. Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res. 2011;34:551-558.
19. Ehrentraut H, Weber C, Ehrentraut S, et al. The Toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur J Heart Fail. 2011;13:602-610.
20. Liu YY, Cai WF, Yang HZ, et al. Bacillus Calmette-Guerin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. J Immunol. 2008;180:7349-7357.
21. Ha T, Li Y, Hua F, et al. Reduced cardiac hypertrophy in Toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res. 2005;68:224-234.
22. Jastrzebski M, Czarnecka D, Rajzer M, et al. Increased levels of inflammatory markers in hypertensives with target organ damage. Kardiol Pol. 2006;64:802-809.
23. Hayashi C, Madrigal AG, Liu X, et al. Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses. J Innate Immun. 2010;2:334-343.
24. Solomon SD, Verma A, Desai A, et al.; Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55:241-248.
25. Kuwahata S, Fujita S, Orihara K, et al. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis. 2010;209:248-254.